From the Guidelines

Beta-glucuronidase is an enzyme produced by gut microbiota that can modify the pharmacokinetics of various drugs, including anticancer therapies.

Beta-glucuronidase is an enzyme that plays a crucial role in the metabolism of certain drugs, such as irinotecan, a chemotherapeutic agent used to treat metastatic colorectal cancer 1.
This enzyme is produced by the gut microbiota and can influence the therapeutic outcomes and side effects of chemotherapy and immunotherapy.

The levels of beta-glucuronidase in the gut microbiota can affect the efficacy and toxicity of immunotherapy, as well as chemotherapy 1.
For example, high levels of beta-glucuronidase can lead to adverse effects of irinotecan, highlighting the importance of considering the gut microbiota when choosing this drug.

Beta-glucuronidase is also used as a control transcript in molecular response assessments, such as in the treatment of chronic myeloid leukemia 1.
In this context, beta-glucuronidase (e.g., GUSB) is used to normalize the expression of BCR-ABL1 transcripts, allowing for accurate monitoring of molecular response to treatment.

From the Research

Beta-glucuronidase is a lysosomal acid hydrolase responsible for the catalytic deconjugation of β-d-glucuronides 2
It is an enzyme that plays an important role in health and disease, as well as medication outcomes, by deconjugating a large number of endogenous and exogenous glucuronides 3
Beta-glucuronidase is involved in the decomposition of beta-D-glucoronides, which are compounds arising from the combination of beta-D-glucoronic acid and various exo- and endogenous compounds 4

Beta-glucuronidase can release the active or inactive parent compound from drug glucuronides, modifying the disposition and action of these drugs 5
The enzyme's activity level in body fluids is deemed a potential biomarker for the diagnosis of some pathological conditions 2
Beta-glucuronidase has been implicated in colon carcinogenesis and certain drug-induced dose-limiting toxicities 3, 2
The activity of beta-glucuronidase increases in many pathological conditions, including liver inflammations, cirrhosis of the liver, and neoplasms 4

Microbiome-encoded β-glucuronidase (GUS) enzymes play important roles in human health by metabolizing drugs in the gastrointestinal (GI) tract 6
An atlas of GUS enzymes in the human intestinal microbiome has identified 3,013 total and 279 unique microbiome-encoded GUS proteins clustered into six unique structural categories 6
The inter-individual variability of GUS proteins in the human GI microbiome has been assessed, and 112 novel microbial GUS enzymes have been discovered 6